- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
44 result(s) found for: Antipyretics.
Displaying page 1 of 3.
EudraCT Number: 2013-002273-22 | Sponsor Protocol Number: 1/2013 | Start Date*: 2013-07-24 |
Sponsor Name:Azienda Ospedaliera L. Sacco - Clinica Pediatrica | ||
Full Title: Efficacy of Pidotimod in the prevention of respiratory infections in healthy children: a randomized, double blind, placebo controlled study. | ||
Medical condition: respiratory infections in children. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002137-39 | Sponsor Protocol Number: V1 25/07/04 | Start Date*: 2004-09-17 |
Sponsor Name: | ||
Full Title: A randomised controlled trial of the combined use of paracetamol and ibuprofen to treat febrile children | ||
Medical condition: Fevers in childhood not asscoaited with severe disease in the immunocompenetent or fever in the immunocompromised host. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001754-21 | Sponsor Protocol Number: 2020-23 | Start Date*: 2020-05-19 |
Sponsor Name:Assistance Publique Hôpitaux de Marseille | ||
Full Title: An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease | ||
Medical condition: COVID-19-associated disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001634-36 | Sponsor Protocol Number: SARCOVID | Start Date*: 2020-04-09 |
Sponsor Name:Rosario García de Vicuña | ||
Full Title: Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection. | ||
Medical condition: COVID-19 infection requiring hospitalization | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002301-23 | Sponsor Protocol Number: BAP00414 | Start Date*: 2005-12-14 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections | |||||||||||||
Medical condition: complicated skin and skin structure infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) LT (Completed) EE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001413-20 | Sponsor Protocol Number: SILCOR-COVID19 | Start Date*: 2020-04-07 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia | ||
Medical condition: COVID19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001270-29 | Sponsor Protocol Number: EFC16858 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19 | |||||||||||||
Medical condition: Coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000260-24 | Sponsor Protocol Number: NAC600-ZI-L-01-06 | Start Date*: 2007-05-21 | |||||||||||
Sponsor Name:ZAMBON ITALIA | |||||||||||||
Full Title: EVALUATION OF THE CLINICAL AND MICROBIOLOGICAL EFFICACY OF N-ACETILCISTEINA 600 MG, IN COMBINATION TO CEFPODOXIMA PROXETILE, IN THE THERAPY OF THE INFECTIONS OF THE HIGH RESPIRATORY WAYS IN ADULT P... | |||||||||||||
Medical condition: Infection of the high respiratory ways in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005526-29 | Sponsor Protocol Number: VP-VLY-686-3501 | Start Date*: 2021-03-31 | |||||||||||
Sponsor Name:Vanda Pharmaceuticals Inc. | |||||||||||||
Full Title: ODYSSEY: A randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe ... | |||||||||||||
Medical condition: inflammatory lung injury associated with severe COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002588-14 | Sponsor Protocol Number: APOTEL-02 | Start Date*: 2014-09-22 | |||||||||||
Sponsor Name:UNI-PHARMA SA | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE IV CLINICAL STUDY OF THE EFFICACY AND SAFETY OF A NEW FORMULATION OF PARACETAMOL FOR THE MANAGEMENT OF FEVER OF INFECTIOUS ORIGIN | |||||||||||||
Medical condition: Fever due to infection of the upper respiratory tract, of the lower respiratory tract, acute pyelonephritis or of the skin and soft tissues. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000166-15 | Sponsor Protocol Number: IVM-2021-01 | Start Date*: 2021-03-03 |
Sponsor Name:Meditop Gyógyszeripari Kft | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients | ||
Medical condition: COVID 19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-001958-36 | Sponsor Protocol Number: SDX_01 | Start Date*: 2022-08-29 |
Sponsor Name:Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste) | ||
Full Title: Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investiga... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was relat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000915-53 | Sponsor Protocol Number: DEXAPAE | Start Date*: 2020-10-08 | |||||||||||
Sponsor Name:Department of Radiology, Rigshospitalet, Denmark | |||||||||||||
Full Title: Randomized double-blind placebo-controlled trial on the efficiency of a single dose dexamethasone in reducing the postembolization syndrome in men undergoing prostatic artery embolization for benig... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000862-13 | Sponsor Protocol Number: V59_67 | Start Date*: 2013-07-18 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals... | |||||||||||||
Medical condition: To assess the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002451-15 | Sponsor Protocol Number: V102_15 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||
Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK... | |||||||||||||
Medical condition: The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those o... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003186-25 | Sponsor Protocol Number: 205352 | Start Date*: 2017-06-01 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Hea... | ||
Medical condition: Healthy volunteers (Infections, Meningococcal) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-005679-18 | Sponsor Protocol Number: GMX04 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:Bio Products Laboratory Limited | |||||||||||||
Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents | |||||||||||||
Medical condition: Primary immunodeficiency diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2006-000835-84 | Sponsor Protocol Number: 30982081-CAP-3001 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:Jansen-Cilag International N.V. | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia | |||||||||||||
Medical condition: Hospitalized community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004174-24 | Sponsor Protocol Number: BAP00248 | Start Date*: 2006-08-24 |
Sponsor Name:Johnson&Johnson Pharmaceutical Research&Development, L.L.C. | ||
Full Title: A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | ||
Medical condition: Hospital-Acquired or Nosocomial Pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005633-10 | Sponsor Protocol Number: DORI INI 2002 | Start Date*: 2008-01-24 | ||||||||||||||||
Sponsor Name:ORTHO MCNEIL JANSSEN SCIENTIFIC AFFAIRS, LLC | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals where Pseudomonas aeruginosa may be a Prevalent Pathogen. | ||||||||||||||||||
Medical condition: Nosocomial and Ventilator-Associated Pneumonia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
